MOCA I Acute Heart Attack Data to be Presented at TCT19admin
First Data from Acute Heart Attack Patients to be Presented at TCT19
Baar, Switzerland, September 23rd 2019
CorFlow Therapeutics AG (“CorFlow”) will present the first clinical results from the MOCA I trial during the upcoming Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco later this week.
The presentation named “Early Experience with CoFI Diagnostic Sequence in Humans” will be presented by Prof. Marco Valgimigli (University Hospital of Bern, Inselspital, Switzerland) during the “DES and Other Emerging Coronary Technologies” innovation session on Friday Sept. 27th.
Prof. Valgimigli, the Principal Investigator of the MOCA I trial, commented: “The CoFI diagnostic sequence is simple and feasible in acute heart attack patients. I’m very pleased to share the very first feasibility human data with the CorFlow technology in acute heart attack patients.”
The CorFlow MOCA (Microvascular Obstruction with the CoFITM System Assessment) trial is a first-in-man clinical trial investigating the CorFlow Controlled Flow Infusion (CoFITM) System in up to 58 heart attack patients. The study is documenting the safety and feasibility of CorFlow’s proprietary dynamic Microvascular Resistance (dMVR) sequence in non-acute (NSTEMI) and acute (STEMI) heart attack patients. At a later stage, the study will also investigate the effect of intracoronary delivery of tirofiban using the CoFITM System. Tirofiban is a small molecule drug belonging to a class of anti-platelet drugs named glycoprotein IIb/IIIa inhibitors.
Dr. Robert S. Schwartz (Minneapolis Heart Institute (Minneapolis, MN, USA) and CorFlow co-Founder) will during the same conference present two posters (TCT935 and TCT936) on preclinical treatment effects using the CoFITM System and further details from the MOCA I trial.
The CoFITM System is a Class III medical device indicated for diagnostic assessment of the coronary microcirculation immediately following PCI and to be a platform for controlled infusion of therapeutic agents into the microcirculation with or without vessel occlusion. Microvascular Obstruction (MVO) is an independent marker for early and late complication rates such as heart failure and death in heart attack patients.
According to CorFlow’s market research, diagnosing and providing a treatment platform for MVO is a big unmet medical need in the interventional cardiology community. The market research shows that more than 140,000 heart attack patients annually in the US and Europe could potentially benefit from the CorFlow CoFITM technology.
Jon H. Hoem, CorFlow’s CEO and co-Founder, said: “We are very happy to have reached the important milestone to enrol acute heart attack patients into the MOCA trial. And we are especially delighted to learn that our substantial experimental work has converted into a procedure which seems safe and feasible in these patients.”
The MOCA I study is funded by CorFlow and through a public grant which the company has been awarded from Innosuisse, the Swiss Innovation Agency.
The Transcatheter Cardiovascular Therapeutics (TCT) conference is one of the world’s largest and most important educational meeting specialising in interventional cardiovascular medicine. For 31 years, TCT has been the centre of cutting-edge educational content, showcasing the latest advances in current therapies and clinical research. TCT is the annual scientific symposium of the Cardiovascular Research Foundation.
TCT is designed for interventional cardiologists, radiologists, clinical cardiologists, scientists, vascular medicine specialists, cardiac and vascular surgeons, nurse practitioners, cath lab technicians, and other healthcare professionals with a special interest in the field of interventional and vascular medicine.
CorFlow Therapeutics is honoured to present the recent clinical findings using the CoFI™ technology during the TCT conference in San Francisco, CA, USA, Sept. 25-29. We look forward to seeing you in San Francisco!